Hold Glenmark Pharma: Q3 was in line though R&D costs hit Ebitda

By: |
Published: February 25, 2019 2:58 AM

FY19-21e EPS down 6-10% given the challenges in US market; TP reduced to Rs 610

Gross margin at 66.3% expanded 173 bps y-o-y/38 bps q-o-q.

Q3 revenue (+16% YoY) was in line, but Ebitda (+35% y-o-y) was 4% below our estimate on higher R&D costs. PAT (adjusted for forex loss) was 9% below estimate. While US revenue grew 16% y-o-y, it was up only 3% q-o-q in USD terms as approvals and market share gains were offset by pricing erosion.

Glenmark expects single-digit growth in US in FY20 and operating margin to improve in FY20 on cost optimisation efforts. It’s Board of Directors has in-principle approved to spin-off its innovation R&D unit (into WOS) as it plans to monetise; it represents 40% of overall R&D spend, in our view. While it plans to reduce net debt (via out-licensing R&D assets), this remained largely flat q-o-q.

Given challenging US generics market, we cut FY19-21e EPS 6-10% with revised TP of Rs 610 (16x FY21e EPS) vs. Rs 640 (17x H1FY21e). Maintain Hold with monetisation of innovative pipeline as key catalyst.

In-line revenues: Revenue grew 16% y-o-y to Rs 25.6 bn, in line with our est., as US revenue (~33% of sales) grew 16% y-o-y/6% q-o-q to Rs 8.6 bn. India revenue (~26% of sales) grew 15% y-o-y to Rs 6.7 bn.
Lower Ebitda on higher R&D cost: Gross margin at 66.3% expanded 173 bps y-o-y/38 bps q-o-q. Despite lower staff and SG&A expenses, Ebitda was 4% below our estimates at Rs 4.3 bn (+35% y-o-y) due to higher R&D costs (+49% y-o-y/+13% q/q). Ebitda margin was at 17% (+237 bps y-o-y).


Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Enough liquidity globally; here’s what will decide how much funds come to Indian stock market | INTERVIEW
2Gold prices off record high level today; may rally to Rs 55,000 by year-end, should you buy or hold?
3Yes Bank’s Rs 15,000 crore FPO opens July 15; SBI readies another Rs 1,760 cr investment in lender